Company ProfilePremium

INVO BIOSCIENCE

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
INVO BIOSCIENCE - Healthcare showcase

Year Founded & Workforce

2007

Industry

Healthcare

Services

Solution
I

INVO BIOSCIENCE Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

INVO BIOSCIENCE Overview

Company Headquarters: Florida, US

Founded: 2007

Workforce: ~N/A

Company Working: INVO Bioscience is a major medical device company that offers simplified and low-cost treatments for patients who are diagnosed with infertility. The company is majorly focused on the treatment of infertility through its assisted reproductive technology (ART). INVO is a FDA-approved medical device used for natural in-vivo incubation of eggs and sperms during the fertilization and early embryo development phase which acts as an alternative to traditional Intrauterine Insemination (IUI) and In-Vitro Fertilization (IVF) systems. It has a strong presence across the Americas.

Strategy

INVO Bioscience focuses on offering economical fertility treatment through its R&D facilities and towards the expansion of its business in Europe and the Middle East and Africa.

Company Snapshot

$0.05M

Revenue

2007

Founded

Florida, US

Headquarters

SWOT Analysis

Strengths

  • Strong presence in North America
  • Strong distribution network

Weaknesses

  • Low global presence

Opportunities

  • Partnerships and agreements
  • Mergers and acquisitions

Threats

  • Stiff competition

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
November 2019AgreementINVO Bioscience entered into a commercialization agreement in Africa, which covers Nigeria, Sudan, Ethiopia, and Uganda to distribute its INVOcell system. This agreement helps INVO Bioscience to enter into the highly populated and underserved infertility market in Africa.

Product Offering

  • INVO BIOSCIENCE
    • Solution

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: sales rose from USD 0.1 Mn in 2016 to USD 0.5 Mn in 2018.
INVO BIOSCIENCE — By Business Segment
Series (USD Mn)201620172018
sales0.10.30.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.